Skip to main content
Erschienen in: Tumor Biology 8/2014

01.08.2014 | Research Article

Interactive effect of glutathione S-transferase M1 and T1 polymorphisms on hepatocellular carcinoma

verfasst von: Chengguang Sui, Jianzhong Ma, Xin He, Guang Wang, Fulu Ai

Erschienen in: Tumor Biology | Ausgabe 8/2014

Einloggen, um Zugang zu erhalten

Abstract

Glutathione S-transferase M1 (GSTM1) and T1 (GSTT1) have been involved in the risk of hepatocellular carcinoma (HCC). However, the interactive effect of GSTM1 and GSTT1 has not been reported previously. The aim of this work was to investigate the interaction and synergism of their variants. We identified nine publications including 1,085 cases and 2,396 controls containing both GSTM1 and GSTT1, and the bi-factor variance analysis of equal repeated test, binary class logistic regression analysis, meta-analysis and probability method were used in this analysis. Data showed there was no interaction between GSTM1 and GSTT1 null genotype variation in HCC development. In addition, individuals with at least one null genotype of GSTM1 and GSTT1 had higher susceptibility to HCC (OR = 2.99, 95 % CI 2.21–4.02). In the control group, the probability of individuals with at least one null genotype of GSTM1 and GSTT1 was 0.6624, while in the case group, the probability to develop HCC with at least one null genotype of GSTM1 and GSTT1 increased to 0.1760, which was considered as the changing characteristics of HCC occurrence in Chinese population. Our result suggests that there would be no direct interaction of GSTM1 and GSTT1 genotype in HCC risk. We speculate that GSTM1 and GSTT1 genotype variations have their own independent function in HCC development and may mutate independently to cause HCC. The synergism variants of the two genes in HCC development have bigger risk in Chinese population.
Literatur
1.
Zurück zum Zitat Kuper H, Tzonou A, Kaklamani E, et al. Tobacco smoking, alcohol consumption and their interaction in the causation of hepatocellular carcinoma. Int J Cancer. 2000;85:498–502.PubMedCrossRef Kuper H, Tzonou A, Kaklamani E, et al. Tobacco smoking, alcohol consumption and their interaction in the causation of hepatocellular carcinoma. Int J Cancer. 2000;85:498–502.PubMedCrossRef
2.
Zurück zum Zitat Wang B, Huang G, Wang D, Li A, Zhipeng X. Null genotypes of GSTM1 and GSTT1 contribute to hepatocellular carcinoma risk: evidence from an updated meta-analysis. J Hepatol. 2010;53:508–18.PubMedCrossRef Wang B, Huang G, Wang D, Li A, Zhipeng X. Null genotypes of GSTM1 and GSTT1 contribute to hepatocellular carcinoma risk: evidence from an updated meta-analysis. J Hepatol. 2010;53:508–18.PubMedCrossRef
3.
Zurück zum Zitat Schütte K, Bornschein J, Malfertheiner P. Hepatocellular carcinoma—epidemiological trends and risk factors. Dig Dis. 2009;27:80–92.PubMed Schütte K, Bornschein J, Malfertheiner P. Hepatocellular carcinoma—epidemiological trends and risk factors. Dig Dis. 2009;27:80–92.PubMed
4.
Zurück zum Zitat Sun G-A, Wang L-Y, Chen C-J, et al. Genetic polymorphisms of glutathione S-transferases M1 and T1 associated with susceptibility to aflatoxin -related hepatocarcinogenesis among chronic hepatitis B carriers a nested case-control study in Taiwan. Carcinogenesis. 2001;22(8):1289–94.PubMedCrossRef Sun G-A, Wang L-Y, Chen C-J, et al. Genetic polymorphisms of glutathione S-transferases M1 and T1 associated with susceptibility to aflatoxin -related hepatocarcinogenesis among chronic hepatitis B carriers a nested case-control study in Taiwan. Carcinogenesis. 2001;22(8):1289–94.PubMedCrossRef
5.
Zurück zum Zitat Gelatti U, Covolo L, Talamini R, et al. N-Acetyltransferase-2, glutathione S-transferase M1 and T1 genetic polymorphisms, cigarette smoking and hepatocellular carcinoma: a case-control study. Int J Cancer. 2005;115:301–6.PubMedCrossRef Gelatti U, Covolo L, Talamini R, et al. N-Acetyltransferase-2, glutathione S-transferase M1 and T1 genetic polymorphisms, cigarette smoking and hepatocellular carcinoma: a case-control study. Int J Cancer. 2005;115:301–6.PubMedCrossRef
6.
Zurück zum Zitat Dong ZH, Yu SZ, Chen GC, Zhao DM, Fi YP. Relationship of GSTT1 and M1 Genotypes and their effects on elevated aflatoxin exposure and increased risk of hepatocellular carcinoma. Tumor Prev Treat Res. 1997;24(6):327–9. Dong ZH, Yu SZ, Chen GC, Zhao DM, Fi YP. Relationship of GSTT1 and M1 Genotypes and their effects on elevated aflatoxin exposure and increased risk of hepatocellular carcinoma. Tumor Prev Treat Res. 1997;24(6):327–9.
7.
Zurück zum Zitat Dong ZH, Zi XL, Yu SZ, Han JS. Relationship between deletion of slutathion S-transferase gene and susceptibility to primary hepatocellular carcinoma. China Public Health J. 1997;16(3):141–2. Dong ZH, Zi XL, Yu SZ, Han JS. Relationship between deletion of slutathion S-transferase gene and susceptibility to primary hepatocellular carcinoma. China Public Health J. 1997;16(3):141–2.
8.
Zurück zum Zitat Bian JC, Shen FM, Shen L, et al. Susceptibility to hepatocellular carcinoma associated with null genotypes of GSTM1 and GSTT1. World J Gastroenterol. 2000;6(2):228–30.PubMed Bian JC, Shen FM, Shen L, et al. Susceptibility to hepatocellular carcinoma associated with null genotypes of GSTM1 and GSTT1. World J Gastroenterol. 2000;6(2):228–30.PubMed
9.
Zurück zum Zitat Liu CZ, Bian JC, Jiang F, Shen FM. Genetic polymorphism of glutathione S-transferase M1, T1, P1 on susceptibility hepatocellular carcinoma. China Public Health. 2002;18(8):935–6. Liu CZ, Bian JC, Jiang F, Shen FM. Genetic polymorphism of glutathione S-transferase M1, T1, P1 on susceptibility hepatocellular carcinoma. China Public Health. 2002;18(8):935–6.
10.
Zurück zum Zitat Wei YP, Ma Y, Deng ZL. Genetic polymorphisms of glutathione S 2transferase M1 and T1 and the risk of hepatocellular carcinoma. Tumor. 2003;23(6):454–66. Wei YP, Ma Y, Deng ZL. Genetic polymorphisms of glutathione S 2transferase M1 and T1 and the risk of hepatocellular carcinoma. Tumor. 2003;23(6):454–66.
11.
Zurück zum Zitat He SJ, Tan JR, Gu YY, Zhong WG, Su SG. Genetic polymorphism analysis of GSTM1、GSTT1 in patients with hepatocellular carcinoma. J Guangxi Med Univ. 2005;22(6):875–6. He SJ, Tan JR, Gu YY, Zhong WG, Su SG. Genetic polymorphism analysis of GSTM1、GSTT1 in patients with hepatocellular carcinoma. J Guangxi Med Univ. 2005;22(6):875–6.
12.
Zurück zum Zitat Deng ZL, Wei YP, Genetic MY. Deletion of GSTM1 and GSTT1 Detoxicated Enzymes in relation to hepatocellular carcinoma in Guangxi. Guangxi Sci. 2005;12(1):55–7. Deng ZL, Wei YP, Genetic MY. Deletion of GSTM1 and GSTT1 Detoxicated Enzymes in relation to hepatocellular carcinoma in Guangxi. Guangxi Sci. 2005;12(1):55–7.
13.
Zurück zum Zitat Long XD, Ma Y, Wei YP, Deng ZL. Study on the detoxication gene gstM1-, gstT1-null and susceptibility to aflatoxin B,-related hepatocellular carcinoma in Guangxi. China J Epidemiol. 2005;26(10):777–81. Long XD, Ma Y, Wei YP, Deng ZL. Study on the detoxication gene gstM1-, gstT1-null and susceptibility to aflatoxin B,-related hepatocellular carcinoma in Guangxi. China J Epidemiol. 2005;26(10):777–81.
14.
Zurück zum Zitat Guo HY, Bian JC, Jiang F, et al. The null genotypes of GSTM1 and GSTT1 and the genetic susceptibility of primary liver cancer in Luoyang. China Tumor. 2005;25(1):58–61. Guo HY, Bian JC, Jiang F, et al. The null genotypes of GSTM1 and GSTT1 and the genetic susceptibility of primary liver cancer in Luoyang. China Tumor. 2005;25(1):58–61.
15.
Zurück zum Zitat Lei Y, Wang C-Y, Xi B, et al. GST polymorphisms are associated with hepatocellular carcinoma risk in Chinese population. World J Gastroenterol. 2011;17(27):3248–56. Lei Y, Wang C-Y, Xi B, et al. GST polymorphisms are associated with hepatocellular carcinoma risk in Chinese population. World J Gastroenterol. 2011;17(27):3248–56.
16.
Zurück zum Zitat Dragani TA. Risk of HCC: genetic heterogeneity and complex genetics. J Hepatol. 2010;52:252–7.PubMedCrossRef Dragani TA. Risk of HCC: genetic heterogeneity and complex genetics. J Hepatol. 2010;52:252–7.PubMedCrossRef
Metadaten
Titel
Interactive effect of glutathione S-transferase M1 and T1 polymorphisms on hepatocellular carcinoma
verfasst von
Chengguang Sui
Jianzhong Ma
Xin He
Guang Wang
Fulu Ai
Publikationsdatum
01.08.2014
Verlag
Springer Netherlands
Erschienen in
Tumor Biology / Ausgabe 8/2014
Print ISSN: 1010-4283
Elektronische ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-014-2071-1

Weitere Artikel der Ausgabe 8/2014

Tumor Biology 8/2014 Zur Ausgabe

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

29.05.2024 Larynxkarzinom Nachrichten

Fast ein Viertel der Personen mit mäßig dysplastischen Stimmlippenläsionen entwickelt einen Kehlkopftumor. Solche Personen benötigen daher eine besonders enge ärztliche Überwachung.

15% bedauern gewählte Blasenkrebs-Therapie

29.05.2024 Urothelkarzinom Nachrichten

Ob Patienten und Patientinnen mit neu diagnostiziertem Blasenkrebs ein Jahr später Bedauern über die Therapieentscheidung empfinden, wird einer Studie aus England zufolge von der Radikalität und dem Erfolg des Eingriffs beeinflusst.

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

28.05.2024 Nebenwirkungen der Krebstherapie Nachrichten

Kardiotoxische Nebenwirkungen einer Therapie mit Immuncheckpointhemmern mögen selten sein – wenn sie aber auftreten, wird es für Patienten oft lebensgefährlich. Voruntersuchung und Monitoring sind daher obligat.

Costims – das nächste heiße Ding in der Krebstherapie?

28.05.2024 Onkologische Immuntherapie Nachrichten

„Kalte“ Tumoren werden heiß – CD28-kostimulatorische Antikörper sollen dies ermöglichen. Am besten könnten diese in Kombination mit BiTEs und Checkpointhemmern wirken. Erste klinische Studien laufen bereits.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.